Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
27
Authors:
1031
Institutions Authors Share
Merck - Rahway, United States of America (USA)
6.000000
0.21
Duke University Health System, United States of America (USA)
3.000000
0.10
Bayer U.S., United States of America (USA)
2.000000
0.07
Mayo Clinic, United States of America (USA)
1.000000
0.03
Inova Heart and Vascular Institute, United States of America (USA)
1.000000
0.03
Wroclaw Medical University, Poland
1.000000
0.03
Canadian VIGOUR Centre, U of A, Canada
1.000000
0.03
University of Colorado Anschutz Medical Campus (CU Anschutz), United States of America (USA)
1.000000
0.03
Centre d'Investigation Clinique - Epidémiologie Clinique (CIC-EC 1433), France
1.000000
0.03
Stanford University School of Medicine, United States of America (USA)
1.000000
0.03
University Medical Center Groningen (UMCG), RUG, Netherlands
1.000000
0.03
Vanderbilt University Medical Center (VUMC), United States of America (USA)
1.000000
0.03
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)
1.000000
0.03
Bayer, Germany
1.000000
0.03
Tufts Medical Center, United States of America (USA)
1.000000
0.03
Bayer Consumer Care AG, Switzerland
1.000000
0.03
San Raffaele University of Rome (UniSanRaffaele), Italy
0.500000
0.02
San Raffaele S.p.A., Italy
0.500000
0.02
University of Mississippi (Ole Miss), United States of America (USA)
0.500000
0.02
National Heart Centre Singapore (NHCS), Singapore
0.500000
0.02
National University of Singapore (NUS), Singapore
0.500000
0.02
Baylor Scott & White Health, United States of America (USA)
0.500000
0.02
Centro Cardiovascular Colombiano Clinica Santa Maria (Clinica Cardio VID), Colombia
0.500000
0.02
University of Antioquia (UdeA), Colombia
0.500000
0.02
Azienda Ospedaliera Papa Giovanni XXIII, Italy
0.500000
0.02
University of Milano-Bicocca (UNIMIB), Italy
0.500000
0.02